Charles Lacey is Professor of Medicine at Hull York Medical School (HYMS), and Honorary Consultant Physician in GU/HIV Medicine at York Teaching Hospital NHS Foundation Trust. He qualified from Guy’s Hospital Medical School, University of London, and undertook postgraduate training in Bristol, Bath, Cambridge, and Oman. He was appointed Consultant Physician in Genitourinary Medicine at the Leeds General Infirmary in 1982, and there developed his interest in sexually transmitted disease research, being awarded grants from the YCRC and MRC to study HPV and candidosis. He also led and advised on HPV and HSV vaccine development in collaboration with industry. In 1996 he was appointed Senior Lecturer in Genitourinary Medicine & Communicable Diseases at Imperial College London, and Honorary Consultant Physician, St Mary’s Hospital, London. He worked in Jonathan Weber’s group, both on HPV clinical and laboratory studies, and also developed a vaginal microbicide research programme, gaining funding from MRC, EC & NIH. In 2004 he moved to HYMS, initially as Reader, and then was appointed to the first Chair in clinical medicine in York in 2007.Career
- Hull York Medical School, University of York (2004 -)
- MD (University of London) 2006
- Imperial College London (1996-2004)
- FRCP 1991
- General Infirmary, Leeds (1982-96)
- Dip Ven 1981
- DRCOG 1979
- MRCP (UK) 1977
- Postgraduate training (1975-82)
- MB BS (University of London) 1974
- L.R.C.P., M.R.C.S., 1974
- Guy’s Hospital Medical School (1968-74)
Professor Charles Lacey’s interests are in vaccines and biomedical protection against infectious diseases. His group is funded by awards from the Medical Research Council, the Wellcome Trust, and the World Health Organization. He is Professor of Medicine at the Centre for Immunology and Infection, Hull York Medical School and Department of Biology, University of York, and Honorary Consultant Physician at York Teaching Hospital.
ProjectsCHAARM: This was a European Commission Framework 7 research programme, studying Combination Highly Active Anti-Retroviral Microbicides. Within CHAARM, the Lacey group and other partners from developed a combination anti-HIV Darunavir + Dapivirine microbicide gel, and conducted a phase 1 trial (DAPIDAR) to assess the safety, pharmacokinetic, and pharmacodynamic parameters of the candidate microbicides. The final study analyses are now in progress
.PROUD: The York sexual health service was one of the centres in the ground breaking PROUD trial, which established the effectiveness of Truvada as pre-exposure prophylaxis for MSM. The trial cohort remains under follow up.
Chlamydial immunology: Recent studies by the Lacey group have focused on Chlamydia trachomatis vaccine development, and chlamydial immunopathogenesis. These showed the efficacy of CT pmpD + a TLR4 agonist as a vaccine candidate, and explored the relationship between local and systemic antibody responses and chlamydial load in C. trachomatis infected women.
Leishmania Therapeutic Vaccine: This project is in collaboration with Prof Paul Kaye in the CII. We have developed a new chimpanzee adenovirus-vectored therapeutic CD8+ T cell-biased vaccine for visceral leishmaniasis. A phase 1 trial conducted in York has established the safety and immunogenicity of the vaccine. We are now working with partners at the Institute for Endemic Diseases, University of Khartoum, Sudan, to conduct a phase 2 trial in patients with post-kala azar dermal leishmaniasis (PKDL) at the trial site in Dooka, Gedaref, Sudan. DoRIS: This is a Global Health Trials award co-funded by MRC, WT, and DfID. We are working with partners at the London School of Hygiene & Tropical Medicine, the National Institute for Medical Research, Tanzania, and the National Cancer Institute, USA, to conduct a dose-ranging study of HPV vaccines in young schoolgirls in Mwanza, Tanzania. The trial aims to establish whether one dose of an HPV vaccine can generate immunological responses in sub-Saharan Africa that are sufficient for protection.
Temperature Logging Vaginal Ring: This project is funded by the WHO and is in collaboration with Queen’s University, Belfast and industrial partners. York will deliver a phase 1 trial of this new medical device. This is a physiological investigation of in vivo temperature variation in the female genital tract.
Research groupsLacey Research Group (Theme 1: Theme 1: From bench to bedside (and back) research, Theme 2: Understanding chronic disease)
Professor Lacey teaches on Phase I & II of the HYMS MB BS programme, and also teaches in Health Sciences & Biology.
Charles Lacey's profile on the York Research Database to see a full list of publications, browse activities and projects, and explore connections, collaborators, related work and more.
- McCormack S, Dunn, DT, Desai M, Dolling DI, Gafos M, Gilson R, Sullivan AK, Clarke A, Reeves I, Schembri G, Mackie M, Bowman C, Lacey CJ, Apea V, Brady M, Fox, J, Taylor S, Antonucci S, Khoo S, Rooney J, Nardone A, Fisher M, McOwan A, Phillips AN, Johnson AM, Gazzard B, Gill ON. Pragmatic open-label randomised trial of pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection: the PROUD study. Lancet 2016; 387(10013):53-60. doi: 10.1016/S0140-6736(15)00056-2. Epub 2015 Sep 9.
- Cosgrove CA, Lacey CJ, Cope A V, Bartolf A, Morris G, Yan C, Baden S, Cole T, Carter D, Brodnicki L, Stoehr W, McCormack S, Shattock RJ. Comparative immunogenicity of an HIV- gp140 Envelope vaccine delivered by parenteral and mucosal routes in female volunteers. PLoS ONE 2016; May 9;11(5):e0152038
- Paes W, Brown N, Brzozowoski AM, Coler R, Reed S, Carter D, Bland M< Kaye PM, Lacey CJRecombinant polymorphic membrane protein D in combination with a novel, second-generation lipid adjuvant protects against intra-vaginal Chlamydia trachomatis infection in mice. Vaccine 2016 Jul 4. pii: S0264-410X(16)30561-8. doi: 10.1016/j.vaccine.2016.06.081.[Epub ahead of print]
Professor Lacey’s group has current collaborations with the London School of Hygiene & Tropical Medicine, Queen’s University Belfast, the National Institute for Medical Research, Tanzania, the University of Khartoum, Sudan, and the National Cancer Institute, USA.